Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

484 RITUXIMAB
(2003): Plosker GL+, Drugs 63(8), 803
(2002): Motto DG+, Isr Med Assoc J 4(11), 1006
Chills (10%)
(2006): Antoniu SA, Expert Opin Investig Drugs 15(9), 1115
(2003): Prescrire Int 12(66), 125
(2003): Boye J+, Ann Oncol 14(4), 520
(2003): Fierro MT+, JAmAcadDermatol49, 281 (passim)
(2003): Rehwald U+, Blood 101(2), 420
(2002): Salopek TG+, JAmAcadDermatol47(5), 785
Death
(2006): Herishanu Y+, Clin Lymphoma Myeloma 6(5), 407
(2006): Iyer A+, Arch Pathol Lab Med 130(10), 1557
(2006): Perceau G+, Br J Dermatol 155(5), 1053
(2006): Scheinfeld N, Dermatol Online J 12(1), 3
(2006): Seifert G+, Haematologica 91(6 Suppl), ECR23
(2003): Sirvent-Von Bueltzingsloewen A+, Med Pediatr Oncol
40(6), 408
(2001): Huhn D+, Blood 98(5), 1326
(2001): Suzan F+, NEnglJMed345(13), 1000
Fever
(2006): Cabanillas F+, Ann Oncol 17(9), 1424 (2 cases)
(2006): Penalver FJ+, Ann Hematol 85(6), 400
(2006): Tamminga RY+, Pediatr Blood Cancer 47(5 Suppl), 714
(2004): Vieira CA+, Transplantation 77(4), 542
(2003): Prescrire Int 12(66), 125
(2003): Boye J+, Ann Oncol 14(4), 520
(2003): Fierro MT+, JAmAcadDermatol49, 281 (passim)
(2003): Rehwald U+, Blood 101(2), 420
Hepatotoxicity
(2006): Iyer A+, Arch Pathol Lab Med 130(10), 1557
(2006): Ozgonenel B+, Am J Hematol 81(4), 302
(2006): Sera T+, Intern Med 45(11), 721 (reactivation)
Hypersensitivity
(2003): Hellerstedt B+, Ann Oncol 14(12), 1792
Infections
(2006): Biehn SE+, Hematol Oncol 24(4), 234
(2006): Cabanillas F+, Ann Oncol 17(9), 1424 (18 cases)
(2006): El Tal AK+, JAmAcadDermatol55(3), 449
(2002): Motto DG+, Isr Med Assoc J 4(11), 1006
Injection-site burning
(2005): Fink-Puches R+, JAmAcadDermatol52(5), 847
Injection-site edema
(2006): Perez-Gala S+, Arch Dermatol 142(11), 1516 (2 cases)
Injection-site erythema
(2005): Fink-Puches R+, JAmAcadDermatol52(5), 847
Injection-site pain
(2005): Fink-Puches R+, JAmAcadDermatol52(5), 847
Injection-site pruritus
(2006): Perez-Gala S+, Arch Dermatol 142(11), 1516
Injection-site reactions (sic)
(2002): Meo P+, Recenti Prog Med 93(7), 421
(2002): Motto DG+, Isr Med Assoc J 4(11), 1006
(2001): Stasi R+, Blood 98(4), 952
(2001): Wood AM, Am J Health Syst Pharm 58(3), 215
Myalgia/Myositis/Myopathy/Myotoxicity (7%)
Nephrotoxicity
(2006): Scheinfeld N, Dermatol Online J 12(1), 3
Serum sickness
(2007): Finger E+, J Clin Rheumatol 13(2), 94
(2007): Todd DJ+, J Rheumatol 34(2), 430
(2006): Schutgens RE, Br J Haematol 135(2), 147
(2006): Tamminga RY+, Pediatr Blood Cancer 47(5 Suppl), 714
(2005): Catuogno M+, Rheumatology (Oxford) 44(3), 406
(2002): Herishanu Y, Am J Hematol 70(4), 329
(2001): D’Arcy CA+, Arthritis Rheum 44, 1717
Upper respiratory infection
(2006): Antoniu SA, Expert Opin Investig Drugs 15(9), 1115
RIVASTIGMINE
Trade name: Exelon (Novartis)
Indications: Alzheimer’s disease and dementia
Category: Cholinesterase inhibitor
Half-life: 1–2 hours
Clinically important, potentially hazardous interactions
with: galantamine
Reactions
Skin
Allergic reactions (sic) (~1%)
Bullous dermatitis (~1%)
Cellulitis (~1%)
Clammy skin (~1%)
Dermatitis (~1%)
Diaphoresis (10%)
Edema (~1%)
Exanthems (~1%)
(2001): Monastero R+, Am J Med 111(7), 583
Exfoliative dermatitis (~1%)
Facial edema (~1%)
Herpes simplex (~1%)
Peripheral edema (~2%)
Psoriasis (~1%)
Purpura (~1%)
Rash (sic) (~2%)
Ulcerations (~1%)
Urticaria (~1%)
Mucosal
Gingivitis (~1%)
Glossitis (~1%)
Sialorrhea (~1%)
Ulcerative stomatitis (~1%)
Vaginitis (~1%)
Xerostomia (~1%)
Hair
Hair – alopecia (~1%)
Eyes
Periorbital edema (~1%)
Other
Hot flashes (~1%)
Infections (~2%)
Myalgia/Myositis/Myopathy/Myotoxicity (20%)
Thrombophlebitis (